Huddersfield Pharmacy Specials has been contracted to provide quality assured GMP and GDP services for the ABC-12 Trial. HPS’ contracted activities include sourcing appropriate packaging, designing and providing Annex 13 compliant labelling, QP IMP certified release of Investigational Medicinal Products and temperature-controlled distribution to sites in the UK. The ABC-12 Trial is exploring the microbiome […]
Huddersfield Pharmacy Specials (HPS) has been contracted to develop new drugs for the MND-SMART clinical trial, which is designed to test potential treatments for motor neuron disease. The MND-SMART trial is adaptive, allowing researchers to modify the drugs being tested based on emerging results. It’s a phase 2/3 trial, which means that if drugs appear […]
Huddersfield Pharmacy Specials (HPS) are delighted to announce that they have been awarded a contract to manufacture sterile investigative medicinal products (IMPs) to be administered to patients diagnosed with Cystic Fibrosis.
On behalf of a clinical care commissioning group, HPS have been contracted to supply a range of medications to a “treatment hub” that has been dedicated for the management of patients presenting with possible CIVID19 related illness.
On behalf of a pharmaceutical company, HPS have commenced the production and supply of an orally administered product specifically aiming at reducing the spread and transmission of COVID19 infections between individuals.
HPS is delighted to announce a significant contract win to develop, manufacture and supply investigative medicinal products for an international trial seeking to establish treatment against COVID19 infection.
HPS have commenced manufacture and supply of hand sanitizer products in-light of the national shortage of such personal hygiene products.
HPS have significantly increased the manufacture of essential medicines required across the NHS in response to enhanced demand related to the treatment of COVID19 positive patients. After continual and on-going consultation with the UK department of Health and NHS England, HPS are seeking to significantly contribute to the nations efforts in managing COVID19 infections.
HPS are delighted to announce the securing of significant medicines over labelling business from a consortium of NHS Trusts.
Following its latest inspection from the UK’s medicines regulator, the MHRA, Huddersfield Pharmacy Specials (HPS) announce today that it has successfully (and additionally) obtained a MIA licence to manufacture non-sterile licenced medicinal products.
